Topics

FDA rejects Heron, Nabriva drug applications, citing manufacturing concerns

07:00 EDT 2 May 2019 | BioPharmaDive

Both biotechs expected approval of their respective pain and anti-infective drugs, but wound up with disappointment and delays.

Original Article: FDA rejects Heron, Nabriva drug applications, citing manufacturing concerns

NEXT ARTICLE

More From BioPortfolio on "FDA rejects Heron, Nabriva drug applications, citing manufacturing concerns"

Quick Search

Relevant Topics

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...